Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

CRISPR screens identify gene targets at breast cancer risk loci

Open access

Abstract

Background: Genome-wide association studies (GWAS) have identified > 200 loci associated with breast cancer risk. The majority of candidate causal variants are in non-coding regions and likely modulate cancer risk by regulating gene expression. However, pinpointing the exact target of the association, and identifying the phenotype it mediates, is a major challenge in the interpretation and translation of GWAS. Results: Here, we show that pooled CRISPR screens are highly effective at identifying GWAS target genes and defining the cancer phenotypes they mediate. Following CRISPR mediated gene activation or suppression, we measure proliferation in 2D, 3D, and in immune-deficient mice, as well as the effect on DNA repair. We perform 60 CRISPR screens and identify 20 genes predicted with high confidence to be GWAS targets that promote cancer by driving proliferation or modulating the DNA damage response in breast cells. We validate the regulation of a subset of these genes by breast cancer risk variants. Conclusions: We demonstrate that phenotypic CRISPR screens can accurately pinpoint the gene target of a risk locus. In addition to defining gene targets of risk loci associated with increased breast cancer risk, we provide a platform for identifying gene targets and phenotypes mediated by risk variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13059-023-02898-w

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CRISPR activation and suppression screens identify BC risk genes that regulate proliferation in 2D, 3D. A Pie chart showing locations of CCVs at 205 BC risk signals identified by GWAS. B Classes of genes selected for functional CRISPR screens. INQ_1 – high-confidence INQUISIT predictions; INQ_2—moderate-confidence INQUISIT predictions; TWAS – identified by transcriptome wide association studies and eQTL studies. C Experimental approach. D Summary of results from 2 and 3D proliferation screens. Known driver gene annotations were from [3]
Fig. 1 CRISPR activation and suppression screens identify BC risk genes that regulate proliferation in 2D, 3D. A Pie chart showing locations of CCVs at 205 BC risk signals identified by GWAS. B Classes of genes selected for functional CRISPR screens. INQ_1 – high-confidence INQUISIT predictions; INQ_2—moderate-confidence INQUISIT predictions; TWAS – identified by transcriptome wide association studies and eQTL studies. C Experimental approach. D Summary of results from 2 and 3D proliferation screens. Known driver gene annotations were from [3]CC BY · PubMed Central
Fig. 2 CRISPR activation and suppression screens identify BC risk genes that regulate tumor growth in mice. A Experimental approach. B Summary of hits from the in vivo screens. C Proliferation in 3D cultures of WT or MEKDD expressing B80-T5 cells following suppression of DUSP4 expression. D DUSP4 protein levels following expression of MEKDD. E Phosphorylation of ERK, JNK and p38 following MEK inhibition. F The effect of MEK inhibitors on proliferation in DUSP4 ko cells
Fig. 2 CRISPR activation and suppression screens identify BC risk genes that regulate tumor growth in mice. A Experimental approach. B Summary of hits from the in vivo screens. C Proliferation in 3D cultures of WT or MEKDD expressing B80-T5 cells following suppression of DUSP4 expression. D DUSP4 protein levels following expression of MEKDD. E Phosphorylation of ERK, JNK and p38 following MEK inhibition. F The effect of MEK inhibitors on proliferation in DUSP4 ko cellsCC BY · PubMed Central
Fig. 3 Olaparib synthetic lethal screens identify BC-risk genes that regulate the DNA repair pathway. A Experimental approach. B B80-T5 cells infected with control or BRCA1-targeting sgRNAs were treated with olaparib for 7 days. C Summary of hits. Known DNA repair genes were annotated based on [33]. D GSEA pathway enrichment analysis of hits (not including background positive control genes). E Validation of selected hits in a singleton experiment using a crystal violet readout. F Enrichment of genes predicted by various computational and statistical methods among the combined hits from all phenotypic screens. INQ_1—high-confidence INQUISIT predictions (genes scored as INQ_1 due to their driver status were downgraded to INQ_2 for this analysis); INQ_2—moderate-confidence INQUISIT predictions; TWAS—identified by transcriptome wide association studies or eQTL studies
Fig. 3 Olaparib synthetic lethal screens identify BC-risk genes that regulate the DNA repair pathway. A Experimental approach. B B80-T5 cells infected with control or BRCA1-targeting sgRNAs were treated with olaparib for 7 days. C Summary of hits. Known DNA repair genes were annotated based on [33]. D GSEA pathway enrichment analysis of hits (not including background positive control genes). E Validation of selected hits in a singleton experiment using a crystal violet readout. F Enrichment of genes predicted by various computational and statistical methods among the combined hits from all phenotypic screens. INQ_1—high-confidence INQUISIT predictions (genes scored as INQ_1 due to their driver status were downgraded to INQ_2 for this analysis); INQ_2—moderate-confidence INQUISIT predictions; TWAS—identified by transcriptome wide association studies or eQTL studiesCC BY · PubMed Central
Fig. 4 Chromatin conformation assays and CRISPRqtl confirm interactions between BC risk loci and genes that score in functional screens. A Summary of HiChIP chromatin interactions observed between BC risk loci and genes that scored in functional screens, where color scale signifies scaled levels of chromatin interaction scores and count. B Example of chromatin interactions between CCVs and ATF7IP. C The regulatory element carrying the protective alleles of CCVs rs16909788, rs17221259, rs11055880 increase ATF7IP promoter activity. Constructs containing all three SNPs were tested using luciferase reporter assays. PRE mutant 1 contains the protective haplotype with rs11055880 altered to the risk allele. PRE mutant 2 contains the risk haplotype with rs16909788 and rs17221259 altered to protective alleles. Bars show mean luciferase intensity relative to promoter activity and error bars represent 95% confidence intervals. P-values were determined by two-way ANOVA followed by Dunnett’s multiple comparisons test (****p < 0.0001). DATF7IP expression was measured in K5 + /K19 − cells 21 days post infection with CRISPRi sgRNAs targeting the ATF7IP CCV-containing enhancer. E Strategy used for CRISPRqtl experiment. F Z-Scores from CRISPRqtl screen of sgRNAs targeting 50 known TSSs. G Genes identified by CRISPRqtl screen as targets of 16 fine mapped BC risk regions that had an INQUISIT level 1 and a CRISPR functional screens hit. H Example of CRISPRqtl results at the chr12:1,391,331–14,913,931. I Zoom into ATF7IP, showing 5 enhancers that score in CRISPRqtl as regulators of ATF7IP expression
Fig. 4 Chromatin conformation assays and CRISPRqtl confirm interactions between BC risk loci and genes that score in functional screens. A Summary of HiChIP chromatin interactions observed between BC risk loci and genes that scored in functional screens, where color scale signifies scaled levels of chromatin interaction scores and count. B Example of chromatin interactions between CCVs and ATF7IP. C The regulatory element carrying the protective alleles of CCVs rs16909788, rs17221259, rs11055880 increase ATF7IP promoter activity. Constructs containing all three SNPs were tested using luciferase reporter assays. PRE mutant 1 contains the protective haplotype with rs11055880 altered to the risk allele. PRE mutant 2 contains the risk haplotype with rs16909788 and rs17221259 altered to protective alleles. Bars show mean luciferase intensity relative to promoter activity and error bars represent 95% confidence intervals. P-values were determined by two-way ANOVA followed by Dunnett’s multiple comparisons test (****p < 0.0001). DATF7IP expression was measured in K5 + /K19 − cells 21 days post infection with CRISPRi sgRNAs targeting the ATF7IP CCV-containing enhancer. E Strategy used for CRISPRqtl experiment. F Z-Scores from CRISPRqtl screen of sgRNAs targeting 50 known TSSs. G Genes identified by CRISPRqtl screen as targets of 16 fine mapped BC risk regions that had an INQUISIT level 1 and a CRISPR functional screens hit. H Example of CRISPRqtl results at the chr12:1,391,331–14,913,931. I Zoom into ATF7IP, showing 5 enhancers that score in CRISPRqtl as regulators of ATF7IP expressionCC BY · PubMed Central
Fig. 5 Summary of genes scoring in CRISPR screens. Fine mapped risk regions that contain INQUISIT level 1 genes that scored in functional CRISPR screens
Fig. 5 Summary of genes scoring in CRISPR screens. Fine mapped risk regions that contain INQUISIT level 1 genes that scored in functional CRISPR screensCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Research works printed but not linked: 1

  1. Tuano NK, Beesley J, Manning M, Shi W, Perlaza-Jimenez L, Malaver-Ortega LF, Paynter J, Black D, Civitarese A, McCue K, Hatzipantelis A, Hillman K, Kaufmann S, Sivakumaran H, Polo JM, Reddel R, Vimla B, French JD, Edwards SL, Powell D, Chenevix-Trench G, Rosenbluh J. CRISPR screens identify gene targets at breast cancer risk loci. Gene Expression Omnibus (GSE219168) 2023; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE219168.

Cited by

See all 30

Metadata

Authors
Tuano, N. K., Beesley, J., Manning, M., Shi, W., Perlaza-Jimenez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D., Civitarese, A., McCue, K., Hatzipantelis, A., Hillman, K., Kaufmann, S., Sivakumaran, H., Polo, J. M., Reddel, R. R., Band, V., French, J. D., Edwards, S. L., Powell, D. R., Chenevix-Trench, G., & Rosenbluh, J.
Affiliations
  • Monash University (AU)
  • QIMR Berghofer Medical Research Institute (AU)
  • The University of Sydney (AU)
  • University of Nebraska Medical Center (US)
Corresponding author
Rosenbluh, Joseph
Venue
Genome Biology
Published
2023-03-29
Volume
24
Issue
1
Pages
59-59
ISSN
  • 1465-6906 (ISSN-L)
  • 1474-760X
OpenAlex
W4361199386
Cited by
30
References
77
Citations by year
2026: 4 · 2025: 8 · 2024: 14 · 2023: 4
FWCI
2.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Genome biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Health and Medical Research Council (1194914, 1135932)
  • DoD (W81XWH1910116)
  • Victorian Cancer Agency (MCRF20035)
  • Isabel and Roderic Allpass
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
CRISPR screen, cell proliferation, DNA damage response, DNA repair, non-coding variants, causal variants, 3D cell culture, immunodeficient mice
MeSH terms
Animals, Neoplasms, Phenotype, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Mice, Genome-Wide Association Study, Clustered Regularly Interspaced Short Palindromic Repeats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRISPR screens identify gene targets at breast cancer risk loci. https://app.cochat.ai/papers/10.1186/s13059-023-02898-w
The paper
Tuano, N. K., Beesley, J., Manning, M., Shi, W., Perlaza-Jimenez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D., Civitarese, A., McCue, K., Hatzipantelis, A., Hillman, K., Kaufmann, S., Sivakumaran, H., Polo, J. M., Reddel, R. R., Band, V., French, J. D., Edwards, S. L., . . . Rosenbluh, J. (2023). CRISPR screens identify gene targets at breast cancer risk loci. Genome Biology. https://doi.org/10.1186/s13059-023-02898-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.